FROM: ELI LILLY AND COMPANY www.lilly.com__ ____________________________________________________________________                Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 U.S.A __________________________________________________________________________________ Phone 317 276 2000_________________________________________________________________ May 16, 2003 Attn: Lilly Buyer RE:ZYPREXA Zydis (olanzapine) Orally Disintegrateing Tablets-Updated Stocking Information We wish to inform you that on June 6, 2003 Lilly will begin supporting ZYPREXA Zydis, the orally disintegrating form of ZYPREXA (olanzapine), with an extensive marketing campaign to community-based psychiatrists and community mental health centers. Until now, ZYPREXA Zydis has primarily been used in institutional and long-term care facilities. The additional marketing efforts to community-based healthcare professionals will be in conjunction with current marketing activities in these inpatient care settings. ZYPREXA Zydis is available in 5 mg, 10 mg, 15 mg, and 20 mg and is indicated for the treatment of schizophrenia, for maintenance of treatment response in schizophrenia, and for acute bipolar mania. ZYPREXA Zydis offers an alternative dosing form for patients who may be unable or reluctant to swallow regular tablets. We anticipate an increase in your current demand for all strengths of ZYPREXA Zydis. Initial Stocking Orders: Stocking incentives may be offered through your wholesaler. Please contact your wholesaler as soon as possible to discuss this opportunity. Sales Forecast: To assist you with your initial stocking quantities, Lilly anticipates that one ZYPREXA Zydis 10 mg 30-count Dose Pack should be stocked in pharmacies purchasing high volumes of ZYPREXA 10 mg tablets. Additionally, Lilly anticipates increased utilization of all four ZYPREXA Zydis strengths. Important Safety Information for ZYPREXA: In short-term schizophrenia and bipolar mania trials, the most common treatment-emergent adverse event associated with ZYPREXA was somnolence. Other common events were dizziness, weight gain, personality disorder (COSTART term for nonaggressive objectionable behavior), constipation, akathisia, postural hypotension, dry mouth, asthenia, dyspepsia, increased appetite, and tremor. A small number of patients experienced asymptomatic elevations of hepatic tranaminase; none of these patients experienced jaundice. Prescribing should be consistent with the need to minimize the risk of tardive dyskinsia, seizures, and orthostatic hypotension. Phenylketonurics should be advised that ZYPREXA Zydis contains phenylalnine. For Prescribing information on ZYPREXA Zydis, please refer to www.ZYPREXA.com or call 1-800-545-5979. Very truly yours, Eli Lilly and Company   Retail Pharmacy Fact Sheet SUPPLIED BY:        Eli Lilly and Company MARKETED BY:       Eli Lilly and Company PRODUCT NAME:    ZYPREXA® Zydis® (Olanzaprine) Orally Disintegrating Tablets Sales Package Size Product Codes  NWP AWP ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4453-85 UPC: 3-0002-4453-85-2 Lilly: TA4453 $187.91 $225.49 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4454-85 UPC: 3-0002-4454-85-2 Lilly: TA4454 $270.35 $324.42 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4455-85 UPC: 3-0002-4455-85-2 Lilly: TA4455 $390.82 $468.98 ZYPREXA Zydis, 5 mg 30-count Dose Pack NDC: 0002-4456-85 UPC: 3-0002-4456-85-2 Lilly: TA4456 $510.60 $612.72 **Stocking incentives may be offered through your wholesaler. Please contact your wholesaler as soon as possible to discuss this opportunity. PRODUCT QUANTITY CASE DIMENSIONS CASE WEIGHT All Presentations of ZYPREXA Zydis 30-count Dose Packs 15 16.5 in x 9.8 in x 7.4 in 3.5 lb DATED ITEM:                           YES PRESCRIPTION LEGEND:           YES TEMPERATURE REQUIREMENTS: 68oF-77oF GUARANTEED SALE:                  12 months' possession required DISTRIBUTION:                         To Eli Lilly and Company Wholesalers RETURNED GOODS:                   See Eli Lilly and Company Return Goods Policy IMPORTANT:                              Eli Lilly and Company uses DDD (Drug Distribution Data) to aid in                                                 monitoring the success of our marketing efforts. Your timely and                                                 accurate reporting of this data for ZYPREXA Zydis will be appreciated.

 

General Pharmacy Classified | Pharmacy Antiques | Pharmacy Collectibles | Rx Computing 

©2000 RPhLink.com The Pharmaceutical Care Network!

Front page | In Pharmacy this week | RxNews1 | RxNews2 | Pharmacy Jobs |

 

 

 

Official complaint of Unfair Business Practices by Meerdink & Associates and Russell Meerdink himself. 

        Re: Official complaint of Unfair Business Practices and Severe Client Confidentiality Violations by Meerdink & Associates

Dear President and Members of the Greenville Market Condo Association:

       As a member of the Greenville Market Condo Association (GMCA) of the Town of Greenville Wisconsin, it is my duty to file this official complaint to the GMCA Board to bring attention to the numerous unfair business practices against RxLink Pharmacy by the Managing Real Estates firm: Meerdink & Associates, Inc. and Russell Meerdink himself.

      Greenville Pharmacy by RxLink opened its doors in 2001 in Greenville, Wisconsin to serve the Greenville Community and the surrounding communities.

      This written complaint will indicate the numerous unfair business practices by Meerdink & Associates and Russell Meerdink.

      The Real Estates Management firm (Meerdink & Associates, Inc. managed by Russell Meerdink), has commited numerous unfair business practices, which have caused irreparable damage to RxLink Pharmacy.  The unfair business practices are now being reported to the proper State and Federal Agencies for review.